DrugPatentWatch Database Preview
Binimetinib - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for binimetinib and what is the scope of freedom to operate?
Binimetinib
is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Binimetinib has two hundred and four patent family members in fifty-one countries.
One supplier is listed for this compound.
Summary for binimetinib
| International Patents: | 204 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 67 |
| Clinical Trials: | 39 |
| Patent Applications: | 162 |
| DailyMed Link: | binimetinib at DailyMed |
Recent Clinical Trials for binimetinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| InxMed (Shanghai) Co., Ltd. | Phase 1 |
| M.D. Anderson Cancer Center | Phase 1 |
| Hospices Civils de Lyon | N/A |
Synonyms for binimetinib
| 181R97MR71 |
| 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide |
| 5-(4-Bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide |
| 5-[(4-Bromo-2-Fluorophenyl)Amino]-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H-Benzimidazole-6-Carboxami |
| 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide |
| 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide |
| 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide |
| 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide |
| 6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide |
| 606143-89-9 |
| A11493 |
| AB0095018 |
| AC-29023 |
| ACWZRVQXLIRSDF-UHFFFAOYSA-N |
| AK175886 |
| AKOS026750517 |
| AOB2072 |
| ARRY 162 |
| ARRY 438162 |
| ARRY-162 |
| ARRY-162,MEK-162 |
| ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162 |
| ARRY-438162 |
| AS-16706 |
| BC600594 |
| BCP06780 |
| Binimetinib (JAN/USAN) |
| Binimetinib (MEK162, ARRY-162, ARRY-438162) |
| Binimetinib [USAN:INN] |
| Binimetinib;MEK-162; ARRY-162;ARRY-438162 |
| C17H15BrF2N4O3 |
| cas:606143-89-9;MEK162 |
| CHEMBL3187723 |
| CS-0627 |
| D10604 |
| DB11967 |
| DTXSID70209422 |
| EX-A1024 |
| FT-0697088 |
| GTPL7921 |
| HMS3652J14 |
| HY-15202 |
| J-516581 |
| KS-0000062X |
| MEK-162 |
| MEK162 |
| MEK162 (ARRY-162, ARRY-438162) |
| MEK162 (Arry-162) |
| MEK162(Binimetinib) |
| Mektovi |
| MFCD22124525 |
| MLS006011180 |
| NCGC00345804-01 |
| NCGC00345804-10 |
| NVP-MEK162 |
| QCR-138 |
| RL04283 |
| s7007 |
| SB16501 |
| SCHEMBL570088 |
| SMR004702949 |
| SW219910-1 |
| UNII-181R97MR71 |
| W-5894 |
| Y1468 |
| ZINC38460704 |
US Patents and Regulatory Information for binimetinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for binimetinib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 233493 | Start Trial |
| Israel | 204419 | Start Trial |
| Slovenia | 2275102 | Start Trial |
| Poland | 2727918 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for binimetinib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2470526 | 2019C/508 | Belgium | Start Trial | PRODUCT NAME: ENCORAFENIB SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/18/1314 20180924 |
| 2727918 | LUC00102 | Luxembourg | Start Trial | PRODUCT NAME: BRAFTOVI - ENCORAFENIB; MEKTOVI - BINIMETINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1314 20180924 |
| 2470526 | LUC00101 | Luxembourg | Start Trial | PRODUCT NAME: BRAFTOVI - ENCORAFENIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1314 20180924 |
| 2727918 | PA2019006 | Lithuania | Start Trial | PRODUCT NAME: BINIMETINIBO IR ENKORAFENIBO, KIEKVIENO BET KURIOMIS FORMOMIS, KURIOMS TAIKOMA PAGRINDINIO PATENTO APSAUGA, DERINYS; REGISTRATION NO/DATE: EU/1/18/1314, EU/1/18/1835 20190920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
